Recurrent Respiratory Papillomatosis


Purpose of Review

Recurrent respiratory papillomatosis (RRP) is a rare disease that continues to cause significant morbidity and occupies a disproportionate amount of otolaryngology care relative to its incidence. As there is no cure for the disease process once it has manifested, recent efforts continue to focus on treatment modalities that delay papilloma re-growth.

Recent Findings

Systemic bevacizumab has been used off-label in severe cases of juvenile RRP with profound reduction in disease volume; however, it requires maintenance therapy of unknown duration. An international adoption of HPV vaccination has led to a decreased incidence of RRP and could potentially eradicate the disease entirely if herd immunity is reached in the USA.


RRP remains a disease with significant morbidity and few successful long-term treatment modalities. For severe cases, systemic bevacizumab shows promise, but comes at significant cost. Ultimately, nationwide HPV vaccination will be the most successful measure to eradicate this disease entirely.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.•

    Novakovic D, Cheng ATL, Zurynski Y, Booy R, Walker PJ, Berkowitz R, et al. A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a National HPV Vaccination Program. J Infect Dis. 2018;217(2):208–12 This study is the first to document the impact of vaccination on RRP incidence.

    Article  Google Scholar 

  2. 2.

    Derkay CS, Bluher AE. Update on recurrent respiratory papillomatosis. Otolaryngol Clin N Am. 2019;52(4):669–79.

    Article  Google Scholar 

  3. 3.

    Kashima HK, Shah F, Lyles A, Glackin R, Muhammad N, Turner L, et al. A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope. 1992;102(1):9–13.

    CAS  Article  Google Scholar 

  4. 4.

    Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol. 2003;101(4):645–52.

    PubMed  Google Scholar 

  5. 5.

    Ruiz R, Achlatis S, Verma A, Born H, Kapadia F, Fang Y, et al. Risk factors for adult-onset recurrent respiratory papillomatosis. Laryngoscope. 2014;124(10):2338–44.

    Article  Google Scholar 

  6. 6.

    Dickens P, Srivastava G, Loke SL, Larkin S. Human papillomavirus 6, 11, and 16 in laryngeal papillomas. J Pathol. 1991;165(3):243–6.

    CAS  Article  Google Scholar 

  7. 7.

    Carvalho CM, Huot L, Charlois AL, Khalfallah SA, Chapuis F, Froehlich P. Prognostic factors of recurrent respiratory papillomatosis from a registry of 72 patients. Acta Otolaryngol. 2009;129(4):462–70.

    Article  Google Scholar 

  8. 8.

    Rabah R, Lancaster WD, Thomas R, Gregoire L. Human papillomavirus-11-associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus-6-associated disease. Pediatr Dev Pathol. 2001;4(1):68–72.

    CAS  Article  Google Scholar 

  9. 9.

    Motz KM, Hillel AT. Office-based management of recurrent respiratory papilloma. Curr Otorhinolaryngol Rep. 2016;4(2):90–8.

    Article  Google Scholar 

  10. 10.

    Zur KB, Fox E. Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a child. Laryngoscope. 2017;127(7):1538–42.

    CAS  Article  Google Scholar 

  11. 11.

    Tam S, Wu CF, Peng HL, Dahlstrom KR, Sturgis EM, Lairson DR. Cost of treating recurrent respiratory papillomavirus in commercially insured and medicaid patients. Laryngoscope. 2020;130(5):1186–94.

    Article  Google Scholar 

  12. 12.

    El-Bitar MA, Zalzal GH. Powered instrumentation in the treatment of recurrent respiratory papillomatosis: an alternative to the carbon dioxide laser. Arch Otolaryngol Head Neck Surg. 2002;128(4):425–8.

    Article  Google Scholar 

  13. 13.

    Pasquale K, Wiatrak B, Woolley A, Lewis L. Microdebrider versus CO2 laser removal of recurrent respiratory papillomas: a prospective analysis. Laryngoscope. 2003;113(1):139–43.

    Article  Google Scholar 

  14. 14.

    Maturo S, Hartnick CJ. Use of 532-nm pulsed potassium titanyl phosphate laser and adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children: initial experience. Arch Otolaryngol Head Neck Surg. 2010;136(6):561–5.

    Article  Google Scholar 

  15. 15.

    Lawlor C, Balakrishnan K, Bottero S, Boudewyns A, Campisi P, Carter J, et al. International Pediatric Otolaryngology Group (IPOG): Juvenile-onset recurrent respiratory papillomatosis consensus recommendations. Int J Pediatr Otorhinolaryngol. 2020;128:109697.

    Article  Google Scholar 

  16. 16.

    Schraff S, Derkay CS, Burke B, Lawson L. American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg. 2004;130(9):1039–42.

    Article  Google Scholar 

  17. 17.

    McMurray JS, Connor N, Ford CN. Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. Ann Otol Rhinol Laryngol. 2008;117(7):477–83.

    Article  Google Scholar 

  18. 18.

    Derkay CS, Malis DJ, Zalzal G, Wiatrak BJ, Kashima HK, Coltrera MD. A staging system for assessing severity of disease and response to therapy in recurrent respiratory papillomatosis. Laryngoscope. 1998;108(6):935–7.

    CAS  Article  Google Scholar 

  19. 19.

    Broekema FI, Dikkers FG. Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2008;265(8):871–9.

    Article  Google Scholar 

  20. 20.

    Armbruster C, Kreuzer A, Vorbach H, Huber M, Armbruster C. Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon alpha-2b. Eur Respir J. 2001;17(4):830–1.

    CAS  Article  Google Scholar 

  21. 21.

    de Bilderling G, Bodart E, Lawson G, Tuerlinckx D, Remacle M, Naesens L, et al. Successful use of intralesional and intravenous cidofovir in association with indole-3-carbinol in an 8-year-old girl with pulmonary papillomatosis. J Med Virol. 2005;75(2):332–5.

    Article  Google Scholar 

  22. 22.

    Sullivan LA, Brekken RA. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs. 2010;2(2):165–75.

    Article  Google Scholar 

  23. 23.

    Rahbar R, Vargas SO, Folkman J, McGill TJ, Healy GB, Tan X, et al. Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2005;114(4):289–95.

    Article  Google Scholar 

  24. 24.

    Rogers DJ, Ojha S, Maurer R, Hartnick CJ. Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children. JAMA Otolaryngol Head Neck Surg. 2013;139(5):496–501.

    Article  Google Scholar 

  25. 25.

    Zeitels SM, Barbu AM, Landau-Zemer T, Lopez-Guerra G, Burns JA, Friedman AD, et al. Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. Ann Otol Rhinol Laryngol. 2011;120(10):627–34.

    Article  Google Scholar 

  26. 26.

    Nagel S, Busch C, Blankenburg T, Schutte W. Treatment of respiratory papillomatosis--a case report on systemic treatment with bevacizumab. Pneumologie. 2009;63(7):387–9.

    CAS  Article  Google Scholar 

  27. 27.

    Mohr M, Schliemann C, Biermann C, Schmidt LH, Kessler T, Schmidt J, et al. Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis. Oncol Lett. 2014;8(5):1912–8.

    CAS  Article  Google Scholar 

  28. 28.•

    Best SR, Mohr M, Zur KB. Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey. Laryngoscope. 2017;127(10):2225–9 This paper documents the largest cohort to date of patients treated with systemic bevacizumab.

    CAS  Article  Google Scholar 

  29. 29.

    Carnevale C, Ferran-De la Cierva L, Til-Perez G, Pena-Zarza JA, Osona-Rodriguez B, Martinez-Lozano J, et al. Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two children. Laryngoscope. 2019;129(4):1001–4.

    Article  Google Scholar 

  30. 30.

    Gates C, Tomboc P, Allison A, Carr M. Bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in an infant. Int J Pediatr Otorhinolaryngol. 2020;129:109762.

    Article  Google Scholar 

  31. 31.

    Hamdi O, Dome J, Zalzal G, Preciado D. Systemic bevacizumab for end-stage juvenile recurrent respiratory papillomas: a case report. Int J Pediatr Otorhinolaryngol. 2020;128:109706.

    Article  Google Scholar 

  32. 32.

    D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944–56.

    CAS  Article  Google Scholar 

  33. 33.

    Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195(11):1582–9.

    Article  Google Scholar 

  34. 34.

    Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300–4.

    PubMed  PubMed Central  Google Scholar 

  35. 35.

    Walker TY, Elam-Evans LD, Singleton JA, Yankey D, Markowitz LE, Fredua B, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years - United States, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(33):874–82.

    Article  Google Scholar 

  36. 36.

    Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Fredua B, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years - United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(33):718–23.

    Article  Google Scholar 

  37. 37.

    Attia AC, Wolf J, Nunez AE. On surmounting the barriers to HPV vaccination: we can do better. Ann Med. 2018;50(3):209–25.

    Article  Google Scholar 

  38. 38.

    Buchinsky FJ, Ruszkay N, Valentino W, Derkay CS, McClay JE, Bastian RW, et al. In RRP, serologic response to HPV is frequently absent and slow to develop. PLoS One. 2020;15(3):e0230106.

    CAS  Article  Google Scholar 

  39. 39.

    Kin Cho Goon P, Scholtz LU, Sudhoff H. Recurrent respiratory papillomatosis (RRP)-time for a reckoning? Laryngoscope Investig Otolaryngol. 2017;2(4):184–6.

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Karen B. Zur.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (include name of committee + reference number) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on PEDIATRIC OTOLARYNGOLOGY: Pediatric Airway and Voice

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ruiz, R., Zur, K.B. Recurrent Respiratory Papillomatosis. Curr Otorhinolaryngol Rep 9, 23–28 (2021).

Download citation


  • Respiratory papillomatosis
  • Bevacizumab
  • Cidofovir
  • HPV vaccine